AUCENTRA’s deep pipeline of proprietary anti-cancer drugs, developed in partnership with the University of South Australia, includes candidates for the treatment of leukemia, ovarian cancer, glioblastoma, colorectal cancer, breast cancer, prostate cancer, liver cancer and lung cancer.
AUCENTRA develops breakthrough classes of drugs to address unmet medical need for some of the most severe cancers. The company’s novel compounds are more targeted and efficacious than current therapeutics, with less side effects.
linkedin.com
Some of these cookies are essential for the website to function correctly, while others may collect your personal information. In some cases, the personal information collected by our cookies may be shared with third party service providers.
For details about the categories of cookies that we use, and to set your cookie preferences, please select ‘More information’ before you continue. For an overview see our Privacy Statement, or review our Privacy Policy in full.